Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combined Sequential Chemotherapy and Radiation Therapies for Early-stage Natural Killer/T-cell Lymphoma
NCT06314334Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Mar 2024
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in Extranodal NK/T-cell lymphoma nasal type (ENKTCL-NT), sponsored by Fudan University. Started Mar 2024; status: recruiting.
02
Drugs
sintilimab
03
Conditions
Extranodal NK/T-cell lymphoma nasal type (ENKTCL-NT)
Beyond the preview
Go deeper on NCT06314334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06314334.